-
Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration
•
Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India Ltd., with any strategic decisions to be approved by the board of directors as necessary. The Swiss pharmaceutical giant cautioned that the assessment may not conclude in 2024 and emphasized that no transaction is guaranteed…
-
Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy
•
Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive treatment table and a dental healing cap (MED) licensed from Germany’s Sirona Dental Systems GmbH and Israel’s Magdent Ltd. This milestone was achieved under the “first pilot, first trial” special medical policy in the Boao…
-
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
•
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down its operations following a strategic review in light of challenging biotech market conditions. This decision initiates a gradual process that includes the divestiture of remaining pipeline assets, delisting from NASDAQ, and deregistration as a corporate…
-
NMPA Launches Pilot Program to Streamline Supplementary Drug Approval Process
•
The National Medical Products Administration (NMPA) has unveiled the “Pilot Work Plan for Optimizing the Review and Approval Procedures of Supplementary Drug Applications,” aimed at enhancing the efficiency of the drug review and approval process. This initiative seeks to streamline the supplementary filing review process for pharmaceutical companies. Under the…
-
Organon Reports Q4 2023 Revenue Growth Driven by Women’s Health and Biosimilars
•
Organon (NYSE: OGN), the U.S.-based pharmaceutical company, has reported its fourth-quarter 2023 financial results, revealing a 3% year-on-year increase in global revenues, reaching USD 6.3 billion in constant currencies. The company’s performance showed marked improvement, with Q4 revenues climbing 8% year-on-year to USD 1.6 billion. Breaking down Q4 performance by…
-
Roche’s Xolair Gains FDA Approval to Combat IgE-Mediated Food Allergies in Patients Aged 1 and Up
•
Roche (SWX: ROG) has announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Xolair (omalizumab) to mitigate allergic reactions, including anaphylaxis, associated with IgE-mediated food allergies in both adult and pediatric patients aged 1 and older. While Xolair is designed to reduce the risk…
-
Ipsen Secures FDA Approval for Onivyde Regimen as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma
•
Ipsen (EPA: IPN, OTCMKTS: IPSEY), the France-based biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for the NALIRIFOX regimen, which combines Onivyde (irinotecan liposome injection) with oxaliplatin, fluorouracil, and leucovorin. This new approval allows for the use of the regimen as…
